Publications by authors named "Odd Johansen"

Claim this Profile
S
Short-term pre-meal whey protein microgel supplementation reduces postprandial glycemia and appetite in adults with overweight: An open-label randomised controlled trial.
Ian J Neeland, Kostas Tsintzas, Bo Ahrén, Robert J Chilton, Ambra Giorgetti, Odd Erik Johansen

Obes Pillars· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral enzyme combination therapy reduces systemic inflammation, urinary CTXII and pain in knee osteoarthritis: a proof-of-mechanism, randomised, crossover, double-blind, placebo-controlled trial.
Yves Henrotin, Thomas Pap, Siddhartha Lieten, Valérie Badot, Jean-Emile Dubuc, Odd Erik Johansen

RMD Open· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low plasma pancreatic lipase as a novel predictor of nutritional target achievement and response to nutritional interventions in malnourished inpatients: Secondary analysis of a randomized clinical trial.
Selina Randegger, Carla Wunderle, Odd Erik Johansen, Pascal Tribolet, Vojtech Pavlicek

Clin Nutr· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of medium-chain triglycerides and whey protein isolate preloads on glycaemia in type 2 diabetes: a randomized crossover study.
Pardeep Pabla, Joanne Mallinson, Aline Nixon, Mia Keeton, Scott Cooper, Odd Erik Johansen

Am J Clin Nutr· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Placebo-Controlled, Single-Center, Crossover Study to Evaluate the Effects of Pre-Meal Whey Protein Microgel on Post-Prandial Glucometabolic and Amino Acid Response in People with Type 2 Diabetes and Overweight or Obesity.
Ian J Neeland, Luiz H de Gregório, Roberto Zagury, Bo Ahrén, Joel Neutel, Odd Erik Johansen

Metabolites· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective review of seven patients with obesity simultaneously treated with a combination of a glucagon-like peptide-1 receptor agonist and a meal replacement product.
Catherine Bacus, Terri-Lynne South, Sonia Raudszus, Odd Erik Johansen

Obes Pillars· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Retrospective review of seven patients with obesity simultaneously treated with a combination of a glucagon-like peptide-1 receptor agonist and a meal replacement product" [Obesity Pillars 12C (2024) 100138].
Catherine Bacus, Terri-Lynne South, Sonia Raudszus, Odd Erik Johansen

Obes Pillars· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oligomalt, a New Slowly Digestible Carbohydrate, Reduces Post-Prandial Glucose and Insulin Trajectories Compared to Maltodextrin across Different Population Characteristics: Double-Blind Randomized Controlled Trials in Healthy Individuals, People with Obesity, and People with Type 2 Diabetes.
Odd Erik Johansen, Joel Neutel, Sanjay Gupta, Barbara Mariani, Gerhard Ufheil

Metabolites· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study.
Jamy D Ard, Ian J Neeland, Amy E Rothberg, Robert J Chilton, Daniel de Luis, Odd Erik Johansen

Diabetes Obes Metab· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
Nikolaus Marx, Ahmed A Kolkailah, Julio Rosenstock, Odd Erik Johansen, Mark E Cooper

JAMA Cardiol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of an oral biodegradable device used for 12 weeks on weight reduction, cardiovascular risk factors, satiety, snacking, and meal size.
Haim Shirin, Ian J Neeland, Donna H Ryan, Daniel de Luis, Albert Lecube, Odd Erik Johansen

Obes Pillars· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a tool to predict the risk of incident heart failure in a general population: the HUNT for HF risk score.
Anne Pernille Ofstad, Cathrine Brunborg, Odd Erik Johansen, Bjørn Mørkedal, Morten W Fagerland

ESC Heart Fail· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oligomalt, a New Slowly Digestible Carbohydrate, Is Well Tolerated in Healthy Young Men and Women at Intakes Up to 180 Gram per Day: A Randomized, Double-Blind, Crossover Trial.
Odd Erik Johansen, Delphine Curti, Maximilian von Eynatten, Andreas Rytz, Anirban Lahiry

Nutrients· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Placebo-Controlled Crossover Study to Evaluate Postprandial Glucometabolic Effects of Mulberry Leaf Extract, Vitamin D, Chromium, and Fiber in People with Type 2 Diabetes.
Mafauzy Mohamed, Roberto Luis Zagury, Kalpana Bhaskaran, Joel Neutel, Barakatun Nisak Mohd Yusof, Odd Erik Johansen

Diabetes Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic kidney disease and cognitive decline in patients with type 2 diabetes at elevated cardiovascular risk.
Chloë Verhagen, Jolien Janssen, Crista A Minderhoud, Esther van den Berg, Christoph Wanner, Odd Erik Johansen

J Diabetes Complications· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Females with type 2 diabetes are at higher risk for accelerated cognitive decline than males: CAROLINA-COGNITION study.
Chloë Verhagen, Jolien Janssen, Geert Jan Biessels, Odd Erik Johansen, Lieza G Exalto

Nutr Metab Cardiovasc Dis· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of a Digital Clinical Decision-Support System in General Practitioners' Management of COPD in Norway.
Varun Kumar Vijayakumar, Tehmina Mustafa, Bjarte Kjell Nore, Kjell Yngvard Garatun-Tjeldstø, Øystein Næss, Odd Erik Johansen

Int J Chron Obstruct Pulmon Dis· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial.
Christoph Wanner, Mark E Cooper, Odd Erik Johansen, Robert Toto, Julio Rosenstock

Clin Kidney J· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia.
Qiuhe Ji, Linong Ji, Yiming Mu, Jiajun Zhao, Bernard Zinman, Odd Erik Johansen

Diabetes Obes Metab· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study.
Geert Jan Biessels, Chloë Verhagen, Jolien Janssen, Esther van den Berg, Gudrun Wallenstein, Odd Erik Johansen

Diabetologia· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007-3015.
Ian J Neeland, Takatoshi Kasai, Silvio E Inzucchi, Brian S Wojeck, Henry K Yaggi, Odd Erik Johansen

Diabetes Care· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
Subodh Verma, C David Mazer, Silvio E Inzucchi, Christoph Wanner, Anne Pernille Ofstad, Odd Erik Johansen

Diabetes Obes Metab· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits.
Darren K McGuire, Silvio E Inzucchi, Odd Erik Johansen, Julio Rosenstock, Jyothis T George

J Pharm Policy Pract· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case report: a patient with thyroid storm, refractory cardiogenic shock, and cardiac arrest treated with Lugol's iodine solution and veno-arterial extra corporal membrane oxygenation support.
Marianne Voll, Kristin Astrid Øystese, Erik Høiskar, Odd Johansen, Cecilie Nyvold

Eur Heart J Case Rep· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial.
Christoph Wanner, Mark E Cooper, Odd Erik Johansen, Robert Toto, Julio Rosenstock

Clin Kidney J· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis